CourtneyÂ D Thornburg

List of Publications by Year
in descending order

78 papers	1,335 citations	516561 16 h-index	360920 35 g-index
80 all docs	80 docs citations	80 times ranked	1607 citing authors

#	Article	IF	Citations
1	Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 2012, 120, 4304-4310.	0.6	204
2	Adherence to Hydroxyurea Therapy in Children with Sickle Cell Anemia. Journal of Pediatrics, 2010, 156, 415-419.	0.9	138
3	Treatment adherence in hemophilia. Patient Preference and Adherence, 2017, Volume 11, 1677-1686.	0.8	117
4	Differences in Health-Related Quality of Life in Children With Sickle Cell Disease Receiving Hydroxyurea. Journal of Pediatric Hematology/Oncology, 2011, 33, 251-254.	0.3	85
5	A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatric Blood and Cancer, 2009, 52, 609-615.	0.8	82
6	Initial Evaluation of the Pediatric PROMISÂ® Health Domains in Children and Adolescents With Sickle Cell Disease. Pediatric Blood and Cancer, 2016, 63, 1031-1037.	0.8	73
7	Neonatal thromboembolic emergencies. Seminars in Fetal and Neonatal Medicine, 2006, 11, 198-206.	1.1	67
8	Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters. Thrombosis Research, 2008, 122, 782-785.	0.8	55
9	Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease. American Journal of Hematology, 2016, 91, 238-242.	2.0	54
10	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127.	0.8	39
11	Regional variation and cost implications of prescribed extended halfâ€life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	1.0	38
12	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	3.8	37
13	Adherence to study medication and visits: Data from the BABY HUG trial. Pediatric Blood and Cancer, 2010, 54, 260-264.	0.8	30
14	Identification and characterization of novel mutations implicated in congenital fibrinogen disorders. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 800-811.	1.0	28
15	The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Therapeutic Advances in Hematology, 2018, 9, 239-249.	1.1	23
16	Venous Thromboembolism in Children with Cancer and Blood Disorders. Frontiers in Pediatrics, 2017, 5, 12.	0.9	19
17	Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Pediatrics, 2022, 150, .	1.0	19
18	Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit. Frontiers in Pediatrics, 2021, 9, 809536.	0.9	18

#	Article	IF	Citations
19	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology, 2016, 56, 298-306.	1.0	14
20	Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 316-326.	0.5	13
21	Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage. Journal of Physical Education and Sports Management, 2018, 4, a003525.	0.5	10
22	Risk factors for cardiovascular disease in children and young adults with haemophilia. Haemophilia, 2018, 24, 747-754.	1.0	10
23	Improving Pediatric Neuro-Oncology Survival Disparities in the United Statesâ€“Mexico Border Region: A Cross-Border Initiative Between San Diego, California, and Tijuana, Mexico. JCO Global Oncology, 2020, 6, 1791-1802.	0.8	10
24	Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Thrombosis Research, 2021, 197, 84-87.	0.8	9
25	Children with sickle cell disease migrating to the United States from subâ€Saharan Africa. Pediatric Blood and Cancer, 2018, 65, e27000.	0.8	8
26	Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients. Pediatric Hematology and Oncology, 2020, 37, 314-325.	0.3	8
27	Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA). Blood, 2010, 116, 270-270.	0.6	8
28	Management and outcomes of pediatric septic thrombophlebitis: a case series. Pediatric Hematology and Oncology, 2020, 37, 344-352.	0.3	7
29	Assessment of Factors Associated With Parental Perceptions of Voluntary Decisions About Child Participation in Leukemia Clinical Trials. JAMA Network Open, 2021, 4, e219038.	2.8	7
30	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 209S-216S.	0.7	6
31	The Evaluation of Hematologic Screening and Perioperative Management in Patients with Noonan Syndrome: A Retrospective Chart Review. Journal of Pediatrics, 2020, 220, 154-158.e6.	0.9	6
32	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	0.6	6
33	Prepare the Way for Hemophilia A Gene Therapy. New England Journal of Medicine, 2022, 386, 1081-1082.	13.9	6
34	Extracellular tyrosylâ€tRNA synthetase cleaved by plasma proteinases and stored in platelet Î±â€granules: Potential role in monocyte activation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1167-1177.	1.0	5
35	Efficacy of Hydroxyurea To Prevent Organ Damage in Young Children with Sickle Cell Anemia.. Blood, 2007, 110, 3386-3386.	0.6	5
36	Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 449-460.	0.5	5

#	Article	IF	Citations
37	How I approach: Previously untreated patients with severe congenital hemophilia A. Pediatric Blood and Cancer, 2018, 65, e27466.	0.8	4
38	Hematologic Manifestations of Nutritional Deficiencies: Early Recognition is Essential to Prevent Serious Complications. Journal of Pediatric Hematology/Oncology, 2019, 41, e182-e185.	0.3	4
39	Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage. Haemophilia, 2020, 26, e353-e355.	1.0	4
40	Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. Blood Advances, 2021, 5, 2079-2086.	2.5	4
41	Study Drug and Visit Adherence: Data from the BABY HUG Trial.. Blood, 2008, 112, 1275-1275.	0.6	4
42	Hydroxyurea Treatment of Young Children with Sickle Cell Anemia: Safety and Efficacy of Continued Treatment â€“ the BABY HUG Follow-up Study. Blood, 2011, 118, 7-7.	0.6	4
43	Hospital-Acquired Venous Thromboembolism in Children: Call-to-Action. Journal of Pediatrics, 2014, 165, 652-653.	0.9	3
44	Ataxia telangiectasia presenting as hyper IgM syndrome without neurologic signs. Annals of Allergy, Asthma and Immunology, 2016, 117, 221-226.	0.5	3
45	The odds and implications of coinheritance of hemophilia A and B. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 931-935.	1.0	3
46	Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. Journal of Perinatology, 2021, 41, 286-294.	0.9	3
47	Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opinion on Drug Safety, 2021, 20, 387-396.	1.0	3
48	Adherence with Hydroxyurea in Children with Sickle Cell Disease. Blood, 2008, 112, 167-167.	0.6	3
49	Etranacogene dezaparvovec for hemophilia B gene therapy. Therapeutic Advances in Rare Disease, 2021, 2, 263300402110588.	0.3	3
50	Anticoagulation in children: personalized strategies. Pediatric Health, 2009, 3, 107-109.	0.3	2
51	Athn 15: Characterizing the Real-World Use of Direct Oral Anticoagulants in Pediatric Patients - Interim Analysis. Blood, 2020, 136, 19-20.	0.6	2
52	Results of an international survey on adherence with anticoagulation in children, adolescents, and young adults: Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	2
53	Neonatal Myocardial Infarction: A Proposed Algorithm for Coronary Arterial Thrombus Management. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011664.	1.4	2
54	Sickle cell anemia: time for personalized prescription of hydroxyurea?Focus on â€œOrganic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokineticsâ€• American Journal of Physiology - Cell Physiology, 2013, 305, C1209-C1210.	2.1	1

#	Article	IF	Citations
55	How we approach: Training pediatric coagulationists. Pediatric Blood and Cancer, 2019, 66, e27982.	0.8	1
56	Scurvy Findings in a Child with Jacobsen Syndrome. JBJS Case Connector, 2019, 9, e0352-e0352.	0.1	1
57	A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor. Haemophilia, 2019, 25, e48-e50.	1.0	1
58	Improving vitamin D testing and supplementation in children with newly diagnosed cancer: A quality improvement initiative at Rady Children's Hospital San Diego. Pediatric Blood and Cancer, 2021, 68, e29217.	0.8	1
59	Do Difficulties In Swallowing Medication Impede The Use Of Hydroxyurea In Children?. Blood, 2013, 122, 2967-2967.	0.6	1
60	Increasing Quality Improvement Capability in a Hemophilia Treatment Center. Blood, 2016, 128, 5908-5908.	0.6	1
61	Impact of Hydroxyurea On Peri-Operative Management and Outcomes in Children with Sickle Cell Anemia.. Blood, 2009, 114, 2567-2567.	0.6	1
62	Risk for Post Thrombotic Syndrome (PTS) Development in Children with Extremity Deep Venous Thrombosis (DVT): Results of the US Centers for Disease Control and Prevention (CDC) Pediatric Thrombosis and Hemostasis Centers.. Blood, 2009, 114, 4000-4000.	0.6	1
63	Real-World Clinical Outcomes in Previously Untreated and Minimally Treated Patients with Congenital Factor VIII Deficiency: The San Diego Experience. Blood, 2020, 136, 31-32.	0.6	1
64	Utilization of Telemedicine for Comprehensive Visits in Patients with Inherited Bleeding Disorders during the COVID-19 Pandemic. Blood, 2020, 136, 10-11.	0.6	1
65	U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis. Blood, 2020, 136, 39-40.	0.6	1
66	Parental informed consent comprehension in childhood cancer clinical trials: Associations with social determinants of health.. Journal of Clinical Oncology, 2022, 40, 6512-6512.	0.8	1
67	Heparin-induced thrombocytopenia and thrombosis syndrome in children. , 0, , 158-165.		0
68	A novel compound heterozygous form of severe protein C deficiency causing bleeding without purpura fulminans. Pediatric Blood and Cancer, 2017, 64, e26626.	0.8	0
69	Your tired, your poor, your huddled masses. Blood, 2019, 133, 2010-2011.	0.6	0
70	Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank. American Heart Journal, 2020, 224, 138-147.	1.2	0
71	The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Data From the Pediatric Registry.. Blood, 2009, 114, 2990-2990.	0.6	0
72	Complications of Implantable Venous Access Devices In Patients with Sickle Cell Disease. Blood, 2010, 116, 1649-1649.	0.6	0

#	Article	IF	Citations
73	Family Perceptions of Barriers and Facilitators of Treatment Protocols for Secondary Stroke Prevention in Children with Sickle Cell Disease. Blood, 2010, 116, 4805-4805.	0.6	0
74	The Physiological and Clinical Effects of Interrupting a Treatment Regimen of Hydroxyurea in Young Children with Sickle Cell Anemia (SCA). Blood, 2011, 118, 2134-2134.	0.6	0
75	Electronic Health Record Tools to Promote Transition Readiness and Knowledge for Adolescents and Young Adults with Hemophilia. Blood, 2019, 134, 4685-4685.	0.6	0
76	Results of the International Survey on Adherence with Anticoagulation in Children, Adolescents and Young Adults. Blood, 2021, 138, 5001-5001.	0.6	0
77	Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices. Blood, 2020, 136, 14-15.	0.6	0
78	Theory-guided assessment of barriers and facilitators to adequate informed consent for childhood cancer clinical trials: Using the Exploration, Preparation, Implementation, Sustainment (EPIS) framework.. Journal of Clinical Oncology, 2022, 40, 6539-6539.	0.8	0